Product nameAnti-Dynamin 2 antibody
See all Dynamin 2 primary antibodies
DescriptionRabbit polyclonal to Dynamin 2
Tested applicationsSuitable for: WB, ICC, IP, ICC/IF, IHC-Fr, IHC-Pmore details
Species reactivityReacts with: Mouse, Rat, Human, Non human primates
Predicted to work with: Cow
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 99% PBS
Concentration information loading...
PurityImmunogen affinity purified
Immunizing Peptide (Blocking)
Our Abpromise guarantee covers the use of ab3457 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use at an assay dependent concentration. Can be blocked with Dynamin 2 peptide (ab4985).|
|ICC||Use at an assay dependent concentration.|
|IP||Use at an assay dependent concentration.|
|IHC-Fr||1/300. PubMed: 17170215|
|IHC-P||Use a concentration of 1 µg/ml.|
FunctionMicrotubule-associated force-producing protein involved in producing microtubule bundles and able to bind and hydrolyze GTP. Most probably involved in vesicular trafficking processes, in particular endocytosis.
Tissue specificityUbiquitously expressed.
Involvement in diseaseDefects in DNM2 are a cause of centronuclear myopathy autosomal dominant (ADCNM) [MIM:160150]; also known as autosomal dominant myotubular myopathy. Centronuclear myopathies (CNMs) are congenital muscle disorders characterized by progressive muscular weakness and wasting involving mainly limb girdle, trunk, and neck muscles. It may also affect distal muscles. Weakness may be present during childhood or adolescence or may not become evident until the third decade of life. Ptosis is a frequent clinical feature. CNMs comprise a wide spectrum of phenotypes, ranging from severe neonatal to mild late-onset familial forms. The most prominent histopathologic features include high frequency of centrally located nuclei in muscle fibers not secondary to regeneration, radial arrangement of sarcoplasmic strands around the central nuclei, and predominance and hypotrophy of type 1 fibers.
Defects in DNM2 are the cause of Charcot-Marie-Tooth disease dominant intermediate type B (CMTDIB) [MIM:606482]. Charcot-Marie-Tooth disease (CMT) is a clinically and genetically heterogeneous disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. CMTDIB is a form of Charcot-Marie-Tooth disease characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec.
Sequence similaritiesBelongs to the dynamin family.
Contains 1 GED domain.
Contains 1 PH domain.
Cellular localizationCytoplasm. Cytoplasm > cytoskeleton. Cell junction > synapse > postsynaptic cell membrane > postsynaptic density. Cell junction > synapse. Microtubule-associated. Also found in the postsynaptic density of neuronal cells.
- Information by UniProt
- CMT2M antibody
- CMTDI1 antibody
- CMTDIB antibody
All lanes : Anti-Dynamin 2 antibody (ab3457)
Lane 1 : SH-SY5Y whole cell lysate
Lane 2 : PC-12
Lane 3 : Neuro-2a
Lane 4 : SK-N-AS
Lane 5 : U- 87 MG
Lane 6 : Rat Brain
All lanes : Goat anti-Rabbit IgG (H+L) HRP conjugated
Immunofluorescent analysis of 4% paraformaldehyde-fixed,0.1% Triton X-100 permeabilized HeLa cells labeling Dynamin 2 with ab3457 at 2 ug/ml followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) secondary antibody at 1/2000 dilution (green).
The nuclear counterstain is DAPI.
ab3457 (1µg/ml) staining Dynamin 2 in human lung using an automated system (DAKO Autostainer Plus).
Sections were rehydrated and antigen retrieved with the Dako 3 in 1 AR buffers EDTA pH 9.0 in a DAKO PT link. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 mins. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 min and detected with Dako envision flex amplification kit for 30 minutes. Colorimetric detection was completed with Diaminobenzidine for 5 minutes. Slides were counterstained with Haematoxylin and coverslipped under DePeX. Please note that, for manual staining, optimization of primary antibody concentration and incubation time is recommended. Signal amplification may be required.
ICC/IF image of ab3457 stained HeLa cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab3457, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
ab3457 staining Dynamin 2 in rat testis tissue by Immunohistochemistry (Frozen sections). Samples were dual-labeled.
Frozen testis sections (7 µm) were fixed with 4% paraformaldehyde (wt/vol) for 10 minutes and permeabilized in 0.1% Triton X-100 (vol/vol) for 4 minutes. Sections were blocked in 1% BSA (wt/vol) for 30 minutes, followed by an overnight incubation of ab3457 and an anti-Arp3 antibody, both at a 1/200 dilution (diluted in 1% BSA). Samples were then incubated for 30 minutes with an Alexa Fluor 488 (green) conjugated secondary, and an Alexa Fluor 555 (red) conjugated secondary, at a dilution of 1/100–1/250 containing 1% BSA. All incubations were performed at room temperature. Counterstained with DAPI (blue).
Western blot detection of Dynamin 2 on mouse testes homogenate using ab3457.
This product has been referenced in:
- Trochet D et al. Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy. EMBO Mol Med 10:239-253 (2018). WB, ICC/IF . Read more (PubMed: 29246969) »
- Ding W et al. Osteopontin deficiency ameliorates Alport pathology by preventing tubular metabolic deficits. JCI Insight 3:N/A (2018). Read more (PubMed: 29563333) »